Elucidating the mechanisms and consequences of clinical HIV-1 resistance to the CCR5 antagonist maraviroc [ 2014 - 2017 ]

Research Grant

Researchers: Prof Paul Gorry (Principal investigator) ,  A/Pr Paul Ramsland ,  Prof Richard Payne

Brief description CCR5 antagonists are a new class of anti-HIV drug, and maraviroc (MVC) is the only CCR5 antagonists that is licensed for use as a HIV treatment. Like all HIV treatments, drug resistance to MVC can develop in patients. This study will determine the mechanism of how HIV becomes resistant to MVC, which will permit the development of improved, second generation CCR5 antagonists, and will reveal ways to determine which patients are more likely to develop MVC resistance.

Funding Amount $AUD 622,732.87

Funding Scheme Project Grants

Notes Standard Project Grant